A landmark experimental vaccine has emerged as the first to treat cancer rather than prevent it, marking a significant shift in oncology. Developed for melanoma, the vaccine is personalized to each patient’s unique cancer mutations, using mRNA to instruct the immune system to recognize and attack tumor cells. After surgical removal of the tumor, patients receive nine doses of the vaccine, with clinical data showing a 42% reduction in recurrence or metastasis over two years. This breakthrough builds on over a century of attempts, beginning with Dr. William Coley’s early observations of tumor regression following infection, and leverages modern advancements like genome sequencing and immune checkpoint inhibitors. While melanoma’s high mutation rate makes it more responsive, researchers are now exploring whether similar approaches can work for other cancers, especially in high-risk individuals like those with genetic predispositions. Although the therapy remains expensive due to its individualized design, the success of this trial opens the door to future "off-the-shelf" preventive vaccines for cancers like breast and colon, potentially allowing early intervention before tumors develop. Despite promising results, long-term survival data and broader clinical validation are still needed to confirm widespread applicability. This innovation represents a transformative step in cancer treatment, shifting from prevention to active immune-based therapy after diagnosis.
From New York Times, I'm Michael Barrow. This is The Daily. Today, a new experimental vaccine could become the first of its kind to treat cancer. My colleague, Health Reporter Nina Agrawal, explains how a century-old idea is finally becoming a reality, and where this breakthrough could lead to next. It's Monday, November 16th. Nina, welcome back to The Daily. Hi, Michael. Thanks for having me. My pleasure. Well, I think it's been a little bit more than a decade since I was a child. And I think it's been a little bit more than a decade since I was a child. If not longer, to develop a vaccine that could be used to treat cancer. But it's really a very challenging thing. Why? You know, if you think about how vaccines work in infectious disease, we give somebody a vaccine to prevent the disease. And flu, COVID. Correct. RSD. And cancer is, even within a specific cancer, it's very varied. It's very heterogeneous. And a person's cancer is not exactly the same as the next person's cancer. So you can't easily vaccinate all individuals against something that's going to be so individualized. Right. Cancer by definition is the extremely unique mutation of a cell that becomes cancerous in your body. And it sounds like you're saying the impediment to a cancer vaccine is that you can immunize the human body against the possibility so far that a cell is going to go rogue. Right. I think here the big breakthrough is actually being able to develop a vaccine that does respond to that individual nature of cancer. So what the scientists were able to do here was treat people who already have cancer with a vaccine that is individualized to that cancer. So very much changing the timeline of a vaccine from before someone gets sick to after they've already gotten cancer. Yeah. The way we traditionally think about vaccines against infectious disease being given when somebody is healthy and has no exposure. And this is a different paradigm where you're using it to treat cancer. Once somebody has already been diagnosed with it. Okay. So let's get into the specifics of exactly how this has worked. So basically what's happened now is that scientists have created a vaccine against melanoma. Skin cancer. So they took patients more than 1100 who had melanoma, stage two, three or four. Pretty serious cancer. Yes. They took patients who have been diagnosed with melanoma, had it surgically removed. They basically have minimal disease left in their body, but they are at high risk for it to come back. And so they thought this was the right window to vaccinate. And what they do is when they remove the tumor, they sequence it's DNA. So they can identify all of the mutations, which are the errors or changes in the DNA that the tumor harbors. So they're really getting down to the genetically specific elements of an individual's cancer. Right. And then what they're doing is they're trying to predict which of those mutations, because in melanoma cancer cell can have hundreds of mutations, they're trying to predict which one of those our immune system can see and recognize and then attack. So basically the way our immune system does that is these mutations produce proteins on the cell service, which kind of are like enemy flags to our immune system. So our immune cells are going around the body. And when they see these unusual abnormal foreign proteins like enemy flags, they know to go and attack the cells. But for a number of reasons, when people get cancer, the immune system doesn't do this completely. Some tumors they are able to hide from the immune system. But the researchers said, okay, we see what are all these mutations that produce these enemy flags. Which ones do we think are the most likely to be perceived as an enemy flag by the immune system? They picked up to 34, they're trying to maximize their chances. And instead of putting the proteins, those enemy flags directly into the body, they put mRNA in. mRNA is messenger RNA. It's something we produce in our bodies naturally. It's instructions from our DNA to making proteins. I remember this from AP biology. Right. So what the scientists are inserting in the body in the vaccine is this mRNA encoding up to 34 of these enemy flags. Wow. And science, man. Yes. And they're personalized to every individual in the hopes that the immune system will see some of those enemy flags mount a response and attack the tumor cells. Let me just summarize. Because this is both fascinating and complicated. These scientists, they are taking a little piece of this melanoma cancer. And they are studying these proteins and then creating a vaccine that inserts instructions for the body to recreate those proteins so that our immune system will see them waving their big protein red flags, see them as enemies, and attack them. And in theory, keep that cancer at bay. You got it. So what happens when this magical process results in a vaccine that's inserting these mRNA instructions into these folks who have melanoma? So in this study, the people with melanoma who got the vaccine received nine doses. It's a lot of vaccine. Yeah. I think the idea is to keep boosting the immune response. And so they received one dose every three weeks. You know, I talked to patients who received it and they might have had a sore arm or flu-like symptoms for a day or two, but basically very minimal side effects for a cancer therapy. Right. And then the researchers followed them. How long did they follow them for? They have data from this trial for two years and they were able to show that the people who received the vaccine were 42% less likely to have the cancer come back than the people who did not. 42% less likely to have the cancer come back. That seems like a big number, is it? Yeah. The experts I talked to say that's on par with some of their biggest breakthroughs. Wow. And the researchers also found that the patients who received the vaccine were less likely not only to have the cancer come back, but they were also less likely to have it spread far in the body or become metastatic. So if it came back, it was less likely to become the worst kind of cancer, metastatic cancer. Right. But this is two years of data. So they don't have overall long-term survival data and scientists need to keep following the patients for years to see if the results hold up. But it is a big deal. So because of this success, the companies that have made this vaccine, which is Merck and Moderna, are planning to apply for FDA approval, and the big question is, will it work for other cancers? If so, which ones could it one day be used to prevent cancer up front? And beyond that, this is a big breakthrough for the idea that vaccines might work to treat cancer. And that's something that scientists have been trying to do and failing it for more than 100 years. We'll be right back. Nina, tell us the story of what sounds like 100 years of frustrating failure when it comes to a vaccine to treat cancer. And then let's talk about whether or not what has happened with this vaccine that works reasonably well against melanoma might represent the beginning of an entirely new era in vaccinating against cancer. So if you ask researchers who work in this field, when was the start? A lot of people will point you to Dr. William Coley, a bone surgeon in the 1890s. Well, we're talking really long time ago. Yeah, more than 100 years. And he kind of stumbled into this principle by accident. He had read about a patient who had spontaneous regression of their tumor, meaning it by itself started to shrink. And it happened after the patient got infected with a bacteria and had a fever. Hmm, because the immune system was in overdrive. I think that's the hypothesis. He didn't really know that at the time. He thought, well, the bacteria has something to do with cancer. And what he did start trying to do was inject the tumors with these bacterial mixtures. And in a few of the patients, he did see tumor regression. He was figuring something out. He probably didn't know exactly what he was.
was figuring. He didn't know. And others also, you know, didn't know. And probably what might have been happening was the bacteria were stimulating an immune response. And because it was being injected right into the tumor, those immune cells were also acting on the tumor. But he didn't know that at the time. And shortly thereafter, it was kind of dismissed as quackery and forgotten. And that's partly because other effective treatments came on the scene, which were radiation and chemotherapy later on. So the idea of a vaccine for cancer. Yeah, kind of petered out. But fast forward to the 1980s. And this idea that the immune system might be used to treat cancer is starting to pick up steam. And it's not necessarily using a vaccine, but finding ways to kind of turn up the immune system, send it into overdrive and realizing that that could be a fruitful treatment. This field is called immunotherapy and the first treatment in that field was approved in I think 1986. Okay. And then a few key developments happen in the 1990s, the 2000s, the 2010s, that I would say really allowed us to get to where we are today. And what are those? So one is being able to sequence the human genome. I mean, that was a project that originally took many years and hundreds of millions if not a billion dollars. And now you can sequence an individual genome for hundreds of dollars. Right. And in just a couple of days. Right. Well, a couple of weeks maybe. Yeah. It's a much faster and cheaper process. So the ability to sequence an individual's genome and an individual cancer genome is really key to being able to find the elements that we can put into a vaccine. Okay. So that's one. Another is the development of a certain kind of immune therapy called immune checkpoint inhibitors. And these are basically a class of drugs that take the breaks off of the immune system. Like the immune system has a natural way of putting the breaks on when, you know, it's responding to some sort of infection or so that you don't like start attacking your own cells or develop some autoimmune condition. Right. And cancer cells kind of hijack that process. And so they're telling the immune system to put the breaks on when actually you want the immune system to be attacking those cells. Passing. So the cancer vaccine is given in conjunction with a drug that does this. And in combination, you get something like that 42 percent reduction in the recurrence of the melanoma. Yeah. For two years. Yes. I mean, and that was a significant change in our understanding was realizing, okay, you might produce a vaccine that elicits an immune response like in a petri dish, but researchers weren't actually seeing a clinical benefit. And one of the reasons was that the immune system was, you know, inhibited. Yes. And so being able to de-inhibit the immune system, being able to take the breaks off the immune system, enable the vaccine to work. Wow. And then there are a lot of thoughts about what the best way to give that vaccine would be. People thought maybe DNA, people thought maybe the actual proteins themselves, maybe mRNA, and none of those is easy or cheap. But with the COVID experience, scientists and Moderna in particular learned how to manufacture mRNA vaccines quickly and at scale. And so that really enabled scientists to figure out how to make this customizable mRNA vaccine. That's individualized to somebody's cancer. So the world of science needed to go through a lot, including the human genome project, which as you said, took so long. It needed the experience as you just said of COVID to master rapid scalable mRNA vaccines. It needed time in the case of COVID trauma to get to this place. Yeah. There were a lot of advancements that were building on each other over the years and that all kind of came to a head in the last 10 to 15 years. Okay. This is very helpful in understanding how we get here and the scientific process. I think the question that anyone who is listening to this episode now has is what if I have cancer, I know someone I love, someone who has cancer and it's not melanoma. It's one of the dozens, if not hundreds of other cancers. What does this development mean for that cancer and for those people? I think scientists are a little bit mixed on what they would tell you based on this trial. Some say melanoma is a pretty unique cancer. It has a lot of mutations, so it's more easy to be seen by the immune system. What works for melanoma may not work for all the other solid tumors, breast cancer, colon cancer, pancreatic cancer. At the same time, there are trials being done in some of these other cancers. Probably the most promising one and the one that is being most closely watched is in pancreatic cancer where a small study of 16 patients showed that patients who received an mRNA vaccine also again after surgery were less likely to have it come back within some time period. That was an early trial, but there is a larger randomized study ongoing and so that is one that's really being closely watched. I think the hope certainly is that researchers can figure out a way to make this work for other cancers as well. But I have to think that the spoke vaccines of the sort we're talking about here are going to be extremely expensive to produce because instead of a company making a vaccine that lots and lots of people can use, they're making a vaccine that is for one person. By definition, that means it's not going to be super cost efficient, right? They're making an individualized vaccine for an individual person. So any vaccine like this would be quite expensive. But in general, cancer therapies today are quite expensive, running in the hundreds of thousands of dollars. Well, so for this to ever become a bigger solution to cancer, do doctors and scientists think that it has to move away from this bespoke solution that you're describing with the melanoma clinical trials? Does it have to be a vaccine that doesn't rely on sequencing just one person's specific tumor? So I don't think scientists are necessarily going to move away all together from the bespoke solution. This is a field that they're really experimenting a lot with, and that's promising. Right. And that's showing promise. But researchers are also looking at the possibility of what they call an off-the-shelf cancer vaccine. And they're looking at that more in the setting of prevention in high-risk patients or intercepting earlier cancers. So for example, colon cancer, people with a genetic syndrome that predisposes them or in breast cancer, people with the BRCA one or two mutations. Right. Meaning essentially, it's in their DNA, it's in their family. Already, yes. So they're already at increased risk. Or people who have a precursor condition, like they have polyps, because you're narrowing the population. And so they're looking at, could we develop vaccines based on proteins that are common across breast cancer, across colon cancer, or across all cancers that you could then use to prevent cancer. So far, it hasn't happened. But there are some promising early studies that show it's a possibility. It's still years away, and it's hard science, and it might fail. But it is where I think researchers are excited about where this might go, and also where it has the possibility to affect the most people. Right. Because that would be the holy grail to look at someone whose family heredity tells us that they're likely to get breast cancer and give them a vaccine at some early point in their life that prevents that breast cancer from ever taking off. That would be amazing. And it sounds like we're maybe a little closer to that now than we were before this melanoma vaccine, but I'm looking at you and wondering if that's entirely something we can say. I mean, I think that work has been going on. Like a we are in general in a place where this field, both people who are looking at vaccines to treat disease, as well as vaccines to prevent disease, overall the field has gotten to a place where that work is much more feasible because of those some of those advancements we talked about. And you know, we have some evidence now that it works to prevent a recurrence, prevent cancer from coming back. The question is, can we move it up earlier? And instead of preventing it from coming back, can we prevent it from ever really forming and taking off in the first place? Right. And meeting the requirements of what we traditionally think of as a vaccine, preventing the thing from ever happening at all. That's the dream. Well, Nina, thank you very much. Thanks so much for having me. We'll be right back. Here's what else you need to know today. Here's what we believe happened yesterday. And at least one of our remote FAA locations, a contractor was doing routine maintenance to switch telecommunication lines from old copper wire and they were bringing it over to fiber.
Over the weekend, U.S. officials gave their fullest accounts so far of what they believe caused the rare ground stock that brought air travel across the country to a halt on Friday night. "Now, the work happening was due to the age of the copper wire that we were replacing. It was such an old wire that it was being discontinued." Even Secretary Sean Duffy blamed work by a contractor to replace an outdated router. That work, Duffy said, caused circuits in the nation's air traffic network, including its radar system, to become overloaded and disrupted. "And when we see that, your safety is paramount. We shut down the airspace, and we do it safely." The ground stock highlighted the vulnerability of America's aging air traffic control system, which Duffy said requires tens of billions of dollars in urgent upgrades. "And." "I have a path to get there. No doubt about it." In an interview on Sunday with CNN, Democratic Senator Chris Van Hollen of Maryland said his effort to unseat Chuck Schumer and become his party's next majority leader in the U.S. Senate is gaining support. "Centers Schumer's team put out a list just the other day of people they said who are voting for Senator Schumer. I can tell you that a number of those people on that list have actually committed to voting for me. And the others are very open to the idea of change. There is a home." Schumer claims he already has enough support to win the election, which is scheduled to be decided by secret ballot on December 1st. But Van Hollen, who is positioning himself as a populist underdog, said that Schumer's support is weaker than it appears. Today's episode was produced by Alex Stern and Chris Benderet with help from Eric Krupke and Carlos Prieto. It was edited by MJ Davis-Lin with help from Annie Minoff, contains music by Mary Luzano, Rowanie Misto and Dan Powell, and was engineered by Alyssa Moxley. Our theme music is by Wonderland. That's it for today. I'm Michael Barrow. See you tomorrow.
Podcast Summary
Key Points:
A new personalized mRNA vaccine, developed for melanoma, targets individual cancer mutations to train the immune system to recognize and attack tumor cells.
The vaccine uses mRNA to deliver instructions for creating proteins from cancer-specific mutations, which act as "enemy flags" for immune detection.
In a two-year trial, patients receiving the vaccine were 42% less likely to experience cancer recurrence or metastasis compared to those who did not.
The breakthrough builds on decades of research, including early work by Dr. William Coley and modern advances in genomics and immunotherapy.
Immune checkpoint inhibitors are used in combination with the vaccine to enhance immune response by removing natural brakes on immune activity.
While effective for melanoma, the approach may not work equally well for other cancers due to differences in mutation profiles and immune visibility.
Researchers are exploring "off-the-shelf" vaccines for high-risk populations, such as those with BRCA mutations or precancerous conditions, to enable broader prevention.
The personalized nature of the therapy makes it expensive, but long-term results and broader applicability remain under active investigation.
Summary:
A landmark experimental vaccine has emerged as the first to treat cancer rather than prevent it, marking a significant shift in oncology. Developed for melanoma, the vaccine is personalized to each patient’s unique cancer mutations, using mRNA to instruct the immune system to recognize and attack tumor cells. After surgical removal of the tumor, patients receive nine doses of the vaccine, with clinical data showing a 42% reduction in recurrence or metastasis over two years.
This breakthrough builds on over a century of attempts, beginning with Dr. William Coley’s early observations of tumor regression following infection, and leverages modern advancements like genome sequencing and immune checkpoint inhibitors. While melanoma’s high mutation rate makes it more responsive, researchers are now exploring whether similar approaches can work for other cancers, especially in high-risk individuals like those with genetic predispositions.
Although the therapy remains expensive due to its individualized design, the success of this trial opens the door to future "off-the-shelf" preventive vaccines for cancers like breast and colon, potentially allowing early intervention before tumors develop. Despite promising results, long-term survival data and broader clinical validation are still needed to confirm widespread applicability. This innovation represents a transformative step in cancer treatment, shifting from prevention to active immune-based therapy after diagnosis.
FAQs
Scientists have developed a personalized mRNA vaccine that targets unique mutations in a patient's melanoma cancer, enabling the immune system to recognize and attack cancer cells after diagnosis.
Unlike traditional vaccines that prevent disease before exposure, this one treats existing cancer by targeting individual mutations in a patient's tumor, effectively using immunotherapy after diagnosis.
Patients receiving the vaccine were 42% less likely to experience cancer recurrence over a two-year period, and were less likely to have the cancer spread to other parts of the body.
The vaccine has been tested specifically on melanoma, a type of skin cancer known for having many mutations that make it more visible to the immune system.
While melanoma has many mutations that make it easier to target, researchers are testing it in other cancers like pancreatic cancer, with early promising results, though broader application is still under investigation.
Each person's cancer has unique genetic mutations. The vaccine is personalized to identify and target these specific mutations, making it more likely to trigger an effective immune response.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.